Beijing Jinyang Likang Pharmaceutical Co., Ltd. was established in November 2003, with a registered capital of 7 million yuan. The registered address is 2nd Floor, Building 22, District 5, 188 west fourth ring south road, Fengtai District, Beijing. The business includes Chinese patent medicines, chemical drug preparations, antibiotics, biochemical drugs, medical devices and health food, making it a modern pharmaceutical company focused on medicines marketing and sales management.

    The company was acquired by Trade Star (Beijing) Pharmaceutical Holding Group in June 2013. Since April 2019, the storage and distribution of drugs have been entrusted to a third-party logistics distribution company (Beijing Meikang Yongzheng Pharmaceutical Co., Ltd.). The warehouse address is Guangyang Street, Industrial Development Zone, Daxing District, Beijing. The company mainly focuses on the distribution and delivery of medicines.

    The company has established a quality management system that is adaptable to the scope and scale of the business: with a perfect organizational structure and qualified staffs of GSP, 145 employees 80% of whom have a bachelor degree or above and the office area is 230 square meters.

    The documents of quality management system are consistent with the actual situation of the company. The computer system can monitor and record the whole process of drug management and quality management in real-time. Adhering to the concept of "quickly responding to customer needs" and following the service tenet of "increasing customer value," the company provides two-way value-added services to upstream suppliers and downstream medical institutions based on its business characteristics. The main business direction of the company is the combination of wholesale and distribution of medicines with terminal customers including military hospitals in Beijing and other 1,000 operating companies and the sales revenue is about 300 million yuan. The company got approved with the new version of the GSP on-site certification inspection on August 2019, making it a good reputation of pharmaceutical company.